Reaction
Bronchitis Bacterial reporting signals
As of the last recalculation, Bronchitis Bacterial appears in 757 FAERS reports alongside 7 co-occurring drug terms. The strongest observed disproportionality signal is INFLIXIMAB-DYYB (PRR 103.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Infliximab-Dyyb | 96 | 103.3 | 103.6 |
| Ciclesonide | 12 | 24.6 | 24.6 |
| Tobramycin Solution | 9 | 20.8 | 20.9 |
| Tobramycin Sulfate | 9 | 20.2 | 20.2 |
| Tobramycin | 13 | 15.1 | 15.1 |
| Budesonide, Glycopyrrolate, And Formoterol Fumarate | 4 | 10.6 | 10.6 |
| Dornase Alfa | 4 | 5.6 | 5.6 |